Immunohistochemical evaluation of the expression of prostate tumor‐association markers in the nude mouse human prostate carcinoma heterotransplant lines PC‐82, PC‐EW, and PC‐EG

Abstract

The biotin-avidin immunoperoxidase assay was used to evaluate the expression of several prostate carcinoma-associated markers in formalin-fixed paraffin-embedded tissue sections of three human prostate nude mouse heterotransplant lines PC-82, PC-EW, and PC-EG. In addition to monoclonal antibodies to PSA and PAP, monoclonal antibodies to five other potentially useful markers for prostate carcinomas (TURP-27, Leu-7, 7E11-C5, PSP-19, and PD41) were tested. Tissues from two or more transplant passages were evaluated. The human prostate target antigens were found to be expressed by one or more of the three heterotransplant lines. The PC-82 and PC-EW lines were the most efficient in terms of expression of multiple prostate carcinoma-associated markers and percentage of tumor cells positive for a given prostate antigen. The staining pattern of each marker, in terms of staining intensity, number of tumor cells stained, and staining location, i.e., membrane, cytoplasmic, or ductal secretions, was similar to what has been observed in tissue sections from human prostate carcinomas. The lack of an appropriate model for evaluating the preclinical potential of these Mabs (especially TURP-27, PSP-19, and PD41) makes the findings of this study of considerable importance, and suggests that these human prostate xenografts may be useful models for exploring the diagnostic and therapeutic potential of these anti-prostate carcinoma monoclonal antibodies.

Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and somatostatin analog RC‐160

“…In the preceeding study [35], we showed that [D-Trp6]-LH-RH and antagonist SB-75 inhibited the growth of xenografts of human prostate tumor PC-82 in nude mice. This model of prostate ade-nocarcinoma, unlike the Dunning R-3327 model, uses human PSA and represents the most frequently occurring type of human prostate cancer [32][33][34]361. In the present experiments, we investigated the efficacy of [D-Trp6]-LH-RH and RC-160 alone and in combination in inhibiting this tumor.…”

Establishment of Short-Term Primary Human Prostate Xenografts for the Study of Prostate Biology and Cancer

“…In 1980, Hoehn and colleagues 1 established the PC-82 in vivo human prostate xenograft model (PC-82); they were the first to demonstrate that human prostate tissue could be transplanted and maintained as a xenograft in the subcutaneous environment of immunocompromised mice. Subsequently, a limited number of additional prostate cancer xenograft models have been established, [2][3][4][5][6][7] and have lead to significant advancements in the study of human prostate cancer. However, there are limitations to the use of xenografts that include the frequency and reliability with which they can be established and the possibility that they become mosaics of human and host tissue throughout time.…”

Serially heterotransplanted human prostate tumours as an experimental model

“…Similar results have been obtained for the prostatic acid phosphatase. As determined by tumour tissue staining, PSA has been found from passage to passage for the serially heterotransplanted tumours PC-82, PC-EW [ 49 ], LuCaP [ 47 ], CWR22 [ 50 ] and for several tumours obtained from distant metastases described by Rubin and coworkers [ 51 ]. Similarly, subrenal capsule-implanted tumours maintained strong PSA expression, at a level similar to the original specimen, even after being passaged three times [ 39 ].…”